PURPOSE: To determine if limited doses of iodinated contrast significantly worsen the underlying @entity177 that had warranted the use of @entity515 for diagnostic angiography. METHODS: The records of 122 consecutive @entity1 who had undergone @entity515 angiography for @entity1095 at our institution over a 5-year period were reviewed. The volume and type of iodinated contrast and the volume of @entity515 administered were recorded. Serum @entity1011 measurements obtained before angiography and from 2 to 3 days after angiography were recorded. RESULTS: One hundred @entity1 had pre-angiography and post-angiography @entity1011 levels available for analysis (51 @entity515 only, 49 @entity515 with iodinated contrast). The average pretreatment @entity1011 level was 2.8+/-1.5 mg/dL (range 1.8-6.6) for the @entity515 only group and 3.0+/-1.4 mg/dL (range 1.8-8.2) for the @entity515 plus iodinated contrast group (p=0.46). After angiography, the mean change in @entity1011 was +0.17+/-0.87 mg/dL for the @entity515 only group and +0.03+/-0.98 mg/dL in the @entity515 plus contrast group (p=0.27). Complications included 1 @entity1 with a failing renal transplant who received iodinated contrast and ultimately required return to hemodialysis. A second @entity1 had a transient 1-mg/dL rise of @entity1011 but did not require dialysis. CONCLUSIONS: This study supports the relative safety of @entity515 angiography with the limited used of iodinated contrast supplementation for diagnostic studies or interventions in azotemic @entity1 with @entity1095 .

Safety of limited supplemental iodinated contrast administration in azotemic XXXX undergoing CO2 angiography.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1095 :: ('MESH:D016491', 'Disease') :: ['peripheral vascular disease'] @entity515 :: ('CHEBI:29334', 'Chemical') :: ['CO(2)'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity1 :: (9606,Species) :: ['patients']
